Gareth J Morgan

High-throughput association testing on DNA pools to identify genetic variants that confer susceptibility to acute myeloid leukemia.

Graham R Law, Sara Rollinson, Soren Germer, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Enhancing cancer clonality analysis with integrative genomics

Shweta S Chavan, Donald J Johann, Cody Ashby, 2015, BMC Bioinformatics.

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

Asta Försti, Lewin Eisele, Hartmut Goldschmidt, 2013, Nature Genetics.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

G. Morgan, M. Drayson, F. Davies, 2003, The New England journal of medicine.

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.

Cheng Li, Paola E Leone, Fiona M Ross, 2006, Blood.

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

Fiona M Ross, Antonino Neri, G. Morgan, 2011, Blood.

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Gordon Cook, David A Cairns, G. Morgan, 2014, Nature Communications.

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

S. Barrans, G. Morgan, I. Carter, 2002, Blood.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Gordon Cook, David A Cairns, Matthew Scales, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Pingping Qu, Bart Barlogie, Antje Hoering, 2017, Haematologica.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Lisa J. Murray, Sean Humphray, D. Bentley, 2013, Leukemia.